Wei Ling is currently the Senior Vice President of Investments with Xeraya Capital. Her area of focus at Xeraya is in medical devices and biotechnology in multiple disease areas.

Wei Ling’s experience spans across both private equity and venture capital investment. Over the years, she has been involved in direct investments, portfolio management including Board representation at investee companies, fund management, fund raising activities and stakeholder management.

Previously, she was with Aureos Capital, a global mid-cap emerging markets private equity fund manager, making direct investments and managing the portfolio in the services and consumer goods sectors. Prior to that, Wei Ling held the finance and fund management role at the Malaysia office of CDC Group plc, the UK Government’s development finance institution and subsequently, Actis Capital, the global emerging markets private equity investment firm following from its de-merger from CDC. Before venturing into investment, she was with KPMG in the assurance and business advisory practice.

Wei Ling is an Australian CPA and a Malaysian Chartered Accountant. She holds a Bachelor of Business (Accountancy) degree with distinction from RMIT University Australia.